title: Fibrin-film stenting in a porcine coronary injury model: efficacy and safety compared with uncoated stents.
abstract: OBJECTIVE
  This study was designed to test the efficacy and safety of a fibrin-film-covered stent compared with that of a bare metal stent in the porcine coronary injury model.
  
  
  BACKGROUND
  Biodegradable stents are a potential method of achieving total lesion coverage and delivering local, lesion-specific drug therapy.
  
  
  METHODS
  Two coronary arteries in each pig were randomly assigned to deployment of either a fibrin-film or a bare tantalum wire-coil stent. An oversized balloon injury, 1.15 to 1.30 times the reference vessel diameter, was induced in each coronary segment before stenting to simulate angioplasty injury. Thirty pigs were studied: group 1 for 28 days (15 pigs); group 2 for 90 days (5 pigs); group 3 for 6 months (5 pigs); group 4 for 1 year (5 pigs).
  
  
  RESULTS
  Two pigs died of occlusion of the bare stent and one of occlusion of the fibrin stent (p > 0.99). There were no significant differences between the fibrin-stented and bare-stented coronary segments with regard to arterial injury. In group 1 (28 days, 14 pigs), the mean neointimal thicknesses in the fibrin-stented and bare-stented groups were 0.57+/-0.31 and 0.57+/-0.27 mm, respectively (p=0.89). In groups 2 to 4 (90 days, four pigs; 6 months, four pigs; 1 year, five pigs), the mean neointimal thicknesses for fibrin- and bare-stented coronary segments at the times studied were 0.48+/-0.26 versus 0.50+/-0.22 mm at 90 days; 035+/-0.04 versus 0.35+/-0.16 mm at 6 months; and 0.33+/-0.14 versus 0.30+/-0.14 mm at 1 year (p=0.98).
  
  
  CONCLUSIONS
  Fibrin-film stents appear to be an excellent candidate for local drug delivery because they can completely and safely cover the stented coronary segment while degrading slowly over 1 to 3 months. This result is important when compared with the poor results of previous studies of synthetic polymer stents.
authors.affiliation: Division of Cardiovascular Diseases, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA.
authors.forename: C J
authors.initials: CJ
authors.lastname: McKenna
authors.forename: A R
authors.initials: AR
authors.lastname: Camrud
authors.forename: G
authors.initials: G
authors.lastname: Sangiorgi
authors.forename: H M
authors.initials: HM
authors.lastname: Kwon
authors.forename: W D
authors.initials: WD
authors.lastname: Edwards
authors.forename: D R
authors.initials: DR
authors.lastname: Holmes
authors.forename: R S
authors.initials: RS
authors.lastname: Schwartz
mesh_terms: D000818:Animals; D003331:Coronary Vessels / Q000473:pathology*; D004867:Equipment Design; D005069:Evaluation Studies as Topic; D005337:Fibrin; D011897:Random Allocation; D015607:Stents; D013552:Swine; D017539:Tunica Intima / Q000473:pathology*
chemical_list: D005337:Fibrin